Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced an upcoming R&D Day scheduled for April 24, 2025, at 9:00 a.m. ET in New York City. The event will showcase the company's research developments in ATP citrate lyase (ACLY) biology and its therapeutic applications for various life-threatening conditions.

The presentation will focus on how ACLY inhibitors could treat rare and chronic liver and kidney diseases. Esperion plans to reveal a new indication and introduce their lead candidate's development pathway. The event will feature key opinion leaders including Dr. Christos S. Mantzoros from Harvard Medical School and Dr. David E. Cohen from Brigham and Women's Hospital.

A live webcast will be available with pre-registration required on Esperion's website Investor section, with replay available for approximately 90 days after the event. In-person attendance requires advanced registration.

News Market Reaction

-8.57%

1 alert

-8.57% News Effect

On the day this news was published, ESPR declined 8.57%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases

ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion’s research and development strategy.

Discussions will highlight Esperion’s advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indication and introduce the lead candidate selected for further development and its planned pathway to approval.

“We are excited to host this R&D Day to share our growing body of scientific evidence that support the therapeutic importance of and promise for targeting the cellular enzyme ACLY, which when dysregulated drives many diseases, including liver and kidney diseases,” said Sheldon Koenig, President and CEO of Esperion. “Allosteric ACLY inhibition is a novel approach to targeting this key enzyme, as abnormalities of ACLY are associated with several diseases effecting multiple cell types. We look forward to advancing our first product candidate from our next-generation ACLY inhibitor discovery program toward an Investigational New Drug Application in order to establish in humans what we have shown in robust pre-clinical work.”

Featured key opinion leaders will be:

• Christos S. Mantzoros, M.D., DSc, Ph.D. h.c. mult., Professor of Medicine at Harvard Medical School; and
• David E. Cohen, M.D., Ph.D., Chief, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital

A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast on the Investor section of the Esperion website. The archived replay will be available approximately two hours after completion of the event and will be archived on the Company's website for approximately 90 days. Please note advanced registration is required for in-person attendance.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When and where is Esperion's (ESPR) R&D Day taking place?

Esperion's R&D Day is scheduled for April 24, 2025, beginning at 9:00 a.m. ET in New York City.

What therapeutic areas will ESPR's R&D Day presentation focus on?

The presentation will focus on ATP citrate lyase (ACLY) biology and its therapeutic potential in rare and chronic liver and kidney diseases.

Who are the key opinion leaders presenting at Esperion's 2025 R&D Day?

Dr. Christos S. Mantzoros from Harvard Medical School and Dr. David E. Cohen from Brigham and Women's Hospital Division of Gastroenterology.

How can investors access Esperion's R&D Day presentation?

Investors can access the event through a live webcast by pre-registering on Esperion's website Investor section, or attend in person with advanced registration.

What is the significance of ACLY inhibition in Esperion's research pipeline?

ACLY inhibition represents a novel approach to targeting this enzyme, which when dysregulated can drive multiple diseases affecting various cell types, particularly in liver and kidney conditions.